<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(9)</volume><submitter>Sahoo SK</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>We studied the temporal course of hypothalamic-pituitary-adrenal (HPA) dysfunction in patients with coronavirus disease 2019 (COVID-19).&lt;h4>Methods&lt;/h4>Three hundred and two patients (median age 54 years (interquartile range (IQR) 42-64), 76% males) were recruited. The HPA axis was evaluated by morning cortisol and adrenocorticotrophic hormone (ACTH) at admission (n = 232). Adrenal insufficiency (AI) during acute illness was defined using a morning cortisol &lt;83 nmol/L. AI at 12 months follow-up was defined using a peak cortisol &lt;406 nmol/L in the ACTH stimulation test (APST) (n = 90). Those with AI at 12 months were further assessed by APST every 6 months for recovery of hypoadrenalism.&lt;h4>Results&lt;/h4>The median morning cortisol and ACTH levels during COVID-19 were 295 (I</pubmed_abstract><journal>Endocrine connections</journal><pagination>e240086</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11378128</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Reversible central adrenal insufficiency in survivors of COVID-19: results from a 24-month longitudinal study.</pubmed_title><pmcid>PMC11378128</pmcid><pubmed_authors>Tripathy N</pubmed_authors><pubmed_authors>Menon JC</pubmed_authors><pubmed_authors>Sahoo SK</pubmed_authors><pubmed_authors>Yadav S</pubmed_authors><pubmed_authors>Nayak M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Reversible central adrenal insufficiency in survivors of COVID-19: results from a 24-month longitudinal study.</name><description>&lt;h4>Objective&lt;/h4>We studied the temporal course of hypothalamic-pituitary-adrenal (HPA) dysfunction in patients with coronavirus disease 2019 (COVID-19).&lt;h4>Methods&lt;/h4>Three hundred and two patients (median age 54 years (interquartile range (IQR) 42-64), 76% males) were recruited. The HPA axis was evaluated by morning cortisol and adrenocorticotrophic hormone (ACTH) at admission (n = 232). Adrenal insufficiency (AI) during acute illness was defined using a morning cortisol &lt;83 nmol/L. AI at 12 months follow-up was defined using a peak cortisol &lt;406 nmol/L in the ACTH stimulation test (APST) (n = 90). Those with AI at 12 months were further assessed by APST every 6 months for recovery of hypoadrenalism.&lt;h4>Results&lt;/h4>The median morning cortisol and ACTH levels during COVID-19 were 295 (I</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-05-08T20:05:57.451Z</modification><creation>2025-02-19T02:34:25.977Z</creation></dates><accession>S-EPMC11378128</accession><cross_references><pubmed>39045873</pubmed><doi>10.1530/EC-24-0086</doi></cross_references></HashMap>